US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 0.31 against a street estimate of 0.26 — a beat of 19.2%.
Analysts rate Ironwood Pharmaceuticals Inc a hold (0 buy, 4 hold, 0 sell out of 4) with an average price target of $6.10.
| Fund | Stake |
|---|---|
| Armistice Capital, LLC | 9.09% |
| BlackRock Inc | 8.09% |
| Sarissa Capital Management LP | 5.56% |
| Bank of America Corp | 5.25% |
| Renaissance Technologies Corp | 4.88% |
| AQR Capital Management LLC | 4.56% |
| State Street Corp | 4.51% |
| Vanguard Portfolio Management, LLC | 4.04% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 IRONWOOD PHARMACEUTICALS, INC. — Q2 2026 SUMMARY HEADLINE NUMBERS • Collaborative arrangements revenue (six months): $219,547 thousand (vs. $126,382 | 2026-08-06 |
| Results announced · Q3 2026 IRONWOOD PHARMACEUTICALS - Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 total revenue: $113.0 million (up 33% vs Q2 2025: $85.2 million) • Q2 | 2026-08-06 |
| Board / officer change · Q2 2026 IRONWOOD PHARMACEUTICALS, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting of Stockholders held June 16, 2026 • 10,000,000 additional share | 2026-06-18 |
| Company announcement · Q2 2026 IRONWOOD PHARMACEUTICALS, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • $200.0 million convertible senior notes repaid in full on June 15, 2026 at sche | 2026-06-15 |
| Board / officer change · Q2 2026 IRONWOOD PHARMACEUTICALS, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • No financial results or revenue figures disclosed in this filing • Document dat | 2026-05-13 |
| Quarterly report · Q1 2026 IRONWOOD PHARMACEUTICALS, INC. — Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Q1 2026 Net Income: $40.8 million (vs. net loss of $37.4 million in Q1 2025 | 2026-05-07 |
| Proxy statement · Q2 2026 IRONWOOD PHARMACEUTICALS, INC. — 2026 PROXY SUMMARY --- CEO COMPENSATION • Thomas McCourt (CEO) total 2025 compensation: Not specified in excerpt p | 2026-04-28 |
| Annual report FY2025 IRONWOOD PHARMACEUTICALS, INC. — 2025 ANNUAL REPORT SUMMARY HEADLINE NUMBERS • Market capitalization (non-affiliate voting stock, June 30, 2025): $1 | 2026-02-26 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Ironwood Pharmaceuticals Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.